Business Wire

DING

2.9.2021 13:02:11 CEST | Business Wire | Press release

Share
Pollen Street Capital Acquires Majority Stake in World’s Largest Mobile Top-up Service Ding

Ding , the world’s largest mobile top-up service, is pleased to announce that it has agreed to sell a majority stake to Pollen Street Capital Private Equity (“Pollen Street”). Pollen Street Capital, a London-based, independent, alternative investment management company, will take a majority stake in the company, in partnership with a substantial investment from the existing founder Mark Roden. The transaction is expected to complete in September.

Commenting on the announcement, Mark Roden, Founder and Chief Executive of Ding said: “We are delighted to announce the investment by Pollen Street Capital. The addition of a strategic investor to our company marks an important milestone for Ding and sets us up for significant growth. Sixteen years ago, we set out with a mission to solve a real problem, to simplify how people separated from their loved ones could stay connected to those back home. At that time, the process was cumbersome and inefficient and today through Ding’s platform we have transformed how people stay connected. We are proud that we are now the global leader and have earned the trust of millions of customers all over the world.”

Founded in 2006 by Mark Roden, Ding is the global leader in international top-up and credit transfers, offering customers the ability to top-up online, on the Ding app, via partners through the Ding API and in over 600,000 retail stores all over the world. Ding now serves millions of customers around the world – who have sent almost a half a billion tops-ups since we began. Pollen Street’s investment will support Ding to continue its strong growth trajectory, expand its technology platform, develop new products and expand into new geographies which will help the Company grow its global customer base and to build out the critical social purpose of keeping communities and families connected.

He added: “Over the years we have explored different investment partners and opportunities but we ultimately chose Pollen Street Capital due to their understanding of our vision for the business, but also due to their extensive and deep expertise in impact investing. We continue to be a socially driven company and we felt that in Pollen Street we had a partner that shared our values.”

He continued: “I would like to thank all our employees past and present who have helped build Ding to become the market leader. With 6 billion prepaid phones in the world and an ever-increasing demand for mobile data there is a significant market opportunity to offer more products and services to current and future customers.”

Ian Gascoigne, Partner at Pollen Street, said: “We are delighted to welcome Mark and his team to the Pollen Street portfolio. Ding has demonstrated an impressive track record and we look forward to partnering with the team to accelerate this growth and maximising the potential of Ding’s multi-channel top-up ecosystem during our investment period. Ding exemplifies Pollen Street’s investment strategy of identifying market leading technology businesses, whose propositions can be enhanced through further investment into technology and an increasing use of data. Ding also represents our commitment to Invest With Impact. As a global platform that connects friends, family, and dispersed communities across the world, Ding allows its customers to send mobile credit and data through a simple, safe, and convenient top-up service. In doing so, Ding fosters closer links and community ties between its users whilst promoting financial inclusion and global connectivity through its highly accessible and easy to use platform.”

Ding was advised by Jefferies, Davis Polk, A&L Goodbody, KPMG and PWC. Pollen Street was advised by Keefe, Bruyette & Woods (a Stifel Company), McCann FitzGerald, Buckley and Deloitte.

Financial terms of the deal were not disclosed.

***ENDS***

About: Ding.com

About: Pollen Street Capital

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release

All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of

Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release

New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that

SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release

SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun

Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release

New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye